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Candidate Functional Promoter Variant in the FOXD3 Melanoblast
Developmental Regulator Gene in Autosomal Dominant Vitiligo
To the Editor:
Generalized vitiligo is an acquired disorder in which white
patches of skin and hair result from autoimmune loss of
melanocytes (Hahn and Nordlund, 2000), often associated
with other autoimmune disorders (Alkhateeb et al, 2003).
Most cases occur in a sporadic family pattern suggesting
polygenic, multifactorial inheritance. However, we previously
described a striking family in which a somewhat unusual
vitiligo phenotype, characterized by progressively coales-
cent diffuse depigmentation and relatively early disease
onset, segregated as an apparent autosomal dominant with
incomplete penetrance (Alkhateeb et al, 2002). By genetic
linkage analysis of this family, we mapped a vitiligo sus-
ceptibility locus, AIS1, to a 7.4-Mb interval of chromosome
1p31 (Alkhateeb et al, 2002).
The AIS1 interval contains only  27 genes, including
an obvious biological candidate, FOXD3, which encodes a
forkhead transcription factor that is a primary regulator of
melanoblast differentiation in the embryonic neural crest
(Sutton et al, 1996; Hromas et al, 1999; Dottori et al, 2001;
Kos et al, 2001), and perhaps also for some endodermal
lineages (Guo et al, 2002). FOXD3 is expressed in all
embryonic neural crest lineages except late-emigrating
melanoblasts (Sutton et al, 1996; Hromas et al, 1999; Dot-
tori et al, 2001; Kos et al, 2001). Inhibition of FOXD3 ex-
pression expands the melanoblast lineage and persistent
FOXD3 overexpression results in developmental failure of
melanoblasts (Dottori et al, 2001). FOXD3 mutations that
result in transcriptional upregulation thus might interfere
with melanoblast differentiation, thereby predisposing to
vitiligo.
To search for AIS1, we prioritized genes in the AIS1 in-
terval based on their known functions and/or involvement in
other diseases, and sequenced the coding and promoter
regions of the eight high-priority (FOXD3, JUN, NFIA) and
intermediate-priority genes (PPAP2B, MPRP1, FLJ10986,
CYP2J2, BBP, ITGB3BP) in the proband of the study family
and an unrelated control. The other genes in the AIS1 in-
terval, mostly prioritized lower because their known func-
tions or disease phenotypes argued against involvement
in vitiligo or autoimmunity, were not studied. We detected
a total of 25 sequence variants, of which 15 were het-
erozygous in the proband and thus potentially consistent
with dominant inheritance. Family analysis showed that only
two of these single-nucleotide polymorphisms (SNPs) (FOX
D3 639G4T and NFIA [IVS]3 þ80G4T) co-segregated
with vitiligo in the study family and were not common var-
iants. NFIA IVS3 þ80G4T is located deep within an intron
and does not create a potential cryptic splice site, whereas
FOXD3 639G4T is located in the transcriptional promot-
er, and thus seemed much more likely to be of potential
functional significance.
FOXD3 639G4T does not appear in dbSNP, and we
did not detect it in 100 unrelated Caucasian controls and
96 additional unrelated Caucasian vitiligo probands. FOXD3
639G4T thus appears to be a private variant. 50 RACE
(rapid amplification of cDNA ends) analysis of human
FOXD3 mRNA showed that the 639G4T substitution
is located 305 nt upstream of the major FOXD3 mRNA 50
start and 519 nt upstream of a minor 50 start (Fig 1). This
region of the FOXD3 promoter has been remarkably con-
served between humans, mice, rats, dogs, and zebrafish,
with 64% sequence identity over the 171-bp segment
immediately downstream from the 639G4T variant. Al-
though 639G4T is located adjacent to high-likelihood Rc,
XF1, and ZF5 motifs, the variant neither alters these motifs
nor creates any known transcriptional motifs.
To measure the effect of the FOXD3 639G4T variant
on the transcriptional activity of the cis FOXD3 promoter, we
transfected Tera1 teratocarcinoma cells (which express en-
dogenous FOXD3 mRNA; Sutton et al, 1996) and primary
human melanocytes (which do not express endogenous
FOXD3; not shown) with transcriptional reporter constructs
containing the FOXD3 639G wild-type versus 639T var-
iant promoters (nt 927 to 261 relative to the translational
initiation codon) driving transcription of a firefly luciferase
reporter gene. As shown in Fig 2, the transcriptional activity
of the 639T variant promoter was significantly elevated
(activity 150%  26; n¼18; po0.0001 compared with
the 639G wild-type promoter) in transfected Tera1 cells,
whereas the transcriptional activity of the 639T variant
promoter was not elevated (activity 95%  21; n¼9; p¼ 0.7
compared with the 639G wild-type promoter) in trans-
fected melanocytes. The transcriptional activity of the
exogenous 639T variant promoter is thus significantly
greater than that of the 639G wild-type promoter in
transfected cells that are permissive for expression of en-
dogenous FOXD3, but not in cells that do not express en-
dogenous FOXD3. These results are thus consistent with
the hypothesis that the 639T substitution results in ele-
vated FOXD3 transcription in neural crest melanoblast
precursors, potentially suppressing or altering the differen-
tiation profile of the melanoblast lineage.
Abbreviations: IVS, intron; RACE, rapid amplification of cDNA
ends; SNP, single-nucleotide polymorphism
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Figure 1
Alignment of orthologous FOXD3
promoter sequences. Promoter and
50-untranslated sequences of the hu-
man, mouse, rat, dog, and zebrafish
(Danio) FOXD3 orthologues are shown
(translation initiation codon underlined).
Nucleotides identical in all five species
are highlighted in red; the position of
the human 639G4T substitution is
highlighted in light blue. No significant
sequence identity was evident up-
stream of this region. Green arrow
overline indicates the major 50 termi-
nus of human FOXD3 mRNA at nt
344; orange arrow overline indicates
the minor mRNA 50 terminus
at nt 130. Note that Danio FOXD3
mRNA apparently initiates further 50,
approximately at a position indicated
by an asterisk underline. The 50 termi-
nus of human FOXD3 mRNA was de-
termined by 50-RACE using the
GenRacer Kit (Invitrogen, Carlsbad,
California), 1 mg Tera1 total RNA, and
gene-specific primers 50-CAACA
CCGCCCTTGCAGC-30 and 50-ACAT
GTCGCTGGCGCTGC-30.
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To determine whether functional variation in FOXD3
might occur in other multiplex vitiligo families, we se-
quenced 3680 bp spanning the entire FOXD3 gene and
promoter (nt 1492 to þ 2188) in two affected members of
each of six small Caucasian multiplex vitiligo families, and
we used DHPLC to screen for variation in the FOXD3 pro-
moter region in probands of another 91 small Caucasian
vitiligo families and 96 unrelated Caucasian controls. Se-
quence variants detected in vitiligo probands were then
tested for co-segregation with vitiligo in the families in which
they occurred. We thereby detected 13 additional FOXD3
SNP, all relatively uncommon and none that consistently co-
segregated with vitiligo in the small families in which they
were found.
Whereas the FOXD3 639G4T promoter substitution
may be the cause of AIS1-dependent vitiligo in the original
study family, variation in the FOXD3 structural gene or its
immediate vicinity clearly is not a frequent genetic risk fac-
tor for vitiligo. Indeed, a number of atypical features of the
study family argue that this family is exceptional, perhaps
unique. First, vitiligo occurs as an apparent autosomal
dominant trait in this very large family, with many individuals
affected. Second, the vitiligo phenotype is atypical, com-
prising slowly progressive diffuse depigmentation, although
invariably diagnosed as ‘‘vitiligo’’ by patients’ dermatolo-
gists. Third, the age of disease onset in this family is rel-
atively early, 12.9  10.1 vs 22.4  16.0 y among vitiligo
patients in general (Alkhateeb et al, 2003). These atypical
characteristics argue that vitiligo in this family may involve a
quite uncommon pathogenic mechanism.
FOXD3 is thus a strong candidate gene for vitiligo sus-
ceptibility in this family, with autosomal dominant vitiligo
linked to chromosome 1p. Nevertheless, identification of
FOXD3 mutations in additional AIS1-linked families, and
more extensive functional studies, will be required to defin-
itively establish the role of FOXD3 in AIS1-linked auto-
immune disease.
These studies were approved by the Colorado Multiple
Institutional Review Board (COMIRB), and were performed
in accord with Declaration of Helsinki principles. Written
informed consent was obtained from all study participants
prior to their participation.
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Figure 2
Transcriptional activity of FOXD3 639T and 639G promoters in
transiently transfected cells. Transfected Tera1 teratocarcinoma cells
(A). Transfected primary human epidermal melanocytes (B). Luciferase
activity of the wild-type 639G promoter was set as 100%. Luciferase
values are the mean of 18 replicates for Tera1 cells and 9 replicates
for melanocytes; error bars represent standard deviations. HEMn-LP
(Cascade Biologics, Portland, Oregon) are primary epidermal me-
lanocytes from a lightly pigmented normal individual, cultured in Me-
dium 154 containing Human Melanocyte Growth Supplement and
penicillin, streptomycin, and amphotericin B (Cascade Biologics). Tera1
is a testicular teratocarcinoma cell line (ATCC) cultured in McCoy’s 5A
medium containing 15% FBS, 100 U per mL penicillin, and 100 mg per
mL streptomycin. 667-bp segments spanning the entire FOXD3 pro-
moter through the major 50 mRNA terminus at nt 344 of both the
639G and 639T alleles were amplified by PCR from DNA of the
proband using primers that create MluI and BglII restriction sites:
50-TTTGCTACGCGTAACACATATGGGAACCTCGTTG-30 and 50-CGCTA-
GATCTAGGGCGCTCGCTACCGCTCCCG-30. PCR products were li-
gated to pCR2.1-TOPO (Invitrogen) and used to transform TOP10F’ E.
coli. Plasmids containing 639G and 639T inserts were identified by
sequencing; the corresponding MluI–BglII fragments were purified and
ligated to pGL3-basic (Promega, Madison, Wisconsin) and used to
transform Escherichia coli XL1-blue (Stratagene, La Jolla, California),
and plasmids containing both the wild-type (pGL3-FOX/-639G) and
mutant (pGL3-FOX/-639T) promoters were identified and re-se-
quenced. Tera1 cells were plated at 1  105 cells per 9.6 cm2 well
and were transfected after 24 h using 1 mg pGL3-basic, pGL3-FOX/-
639G, pGL3-FOX/-639T, or pGL3-control plasmids, plus 20 ng pRL-
SV40 (Renilla luciferase) plasmid as an internal control for transfection
efficiency, using 3 mL FuGENE transfection reagent (Roche, Basel,
Switzerland). For melanocytes, 5  105 log-phase cells were mixed
with 100 mL nucleofector solution (Amaxa, Gaithersburg, Maryland),
and 3 mg of pGL3-basic, pGL3-FOX/-639G, or pGL3-FOX/-639T, plus
60 ng pRL-SV40 plasmid were electroporated using the nucleofector
electroporator (Amaxa) and the U24-specific nucleofector program,
and were then replated in 9.6 cm2 wells. Cells were lysed and assayed
for luciferase expression after 30–42 h for Tera1 cells and  16 h for
melanocytes, which yielded optimal luciferase expression. The dual-
luciferase reporter system (Promega) was used to simultaneously
measure firefly and Renilla luciferase activities utilizing a Monolight
3010 luminometer (Macam Photometrics, Livingston, Scotland, UK),
and the ratio of firefly and Renilla luciferase activities was determined.
Data were analyzed using Student’s t test.
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